Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2021 - 2025)

Historic Other Non Operating Income for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to $98000.0.

  • Tarsus Pharmaceuticals' Other Non Operating Income rose 4626.87% to $98000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$128000.0, marking a year-over-year increase of 9308.86%. This contributed to the annual value of -$1.9 million for FY2024, which is 176153.85% down from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Other Non Operating Income stood at $98000.0, which was up 4626.87% from -$145000.0 recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Other Non Operating Income ranged from a high of $235000.0 in Q4 2021 and a low of -$1.9 million during Q2 2024
  • In the last 5 years, Tarsus Pharmaceuticals' Other Non Operating Income had a median value of -$47500.0 in 2023 and averaged -$200777.8.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Other Non Operating Income surged by 98421.05% in 2023, and later crashed by 403617.02% in 2024.
  • Tarsus Pharmaceuticals' Other Non Operating Income (Quarter) stood at $235000.0 in 2021, then tumbled by 91.91% to $19000.0 in 2022, then surged by 984.21% to $206000.0 in 2023, then crashed by 67.48% to $67000.0 in 2024, then surged by 46.27% to $98000.0 in 2025.
  • Its Other Non Operating Income was $98000.0 in Q3 2025, compared to -$145000.0 in Q2 2025 and -$81000.0 in Q1 2025.